Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease.

摘要: In a pharmacokinetic study with Humate-P including six patients various types of von Willebrand disease, median half-life 11.3 h for vWF:RCoF and 15.2 vWF:Ag was found. The value in vivo recovery (IVR) estimated as 2.10 IU dL-1 plasma per 1 substituted kg-1 b.w. (or 73%), 1.88 69%); FVIII:C 2.69 99%). Transient postinfusion shortening or normalization previously prolonged bleeding time observed all patients. retrospective involving 97 disease types, clinical efficacy safety treatment Haemate-P 73 surgical interventions, 344 separate events, 93 other events 20 cycles prophylactic were evaluated. rated good to excellent 99% the surgeries, 97% episodes, 86% treatments. overall tolerability good. Adverse possibly probably associated use Humate-P/Haemate-P rare, non-serious nature mild moderate their intensity.